- Home
- ADAP vs PROF Comparison
ADAP vs PROF Comparison
Compare ADAP & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- PROF
- Stock Information
- Founded
- ADAP 2008
- PROF N/A
- Country
- ADAP United Kingdom
- PROF Canada
- Employees
- ADAP N/A
- PROF N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- PROF Medical/Dental Instruments
- Sector
- ADAP Health Care
- PROF Health Care
- Exchange
- ADAP Nasdaq
- PROF Nasdaq
- Market Cap
- ADAP 299.0M
- PROF 238.5M
- IPO Year
- ADAP 2015
- PROF N/A
- Fundamental
- Price
- ADAP $1.09
- PROF $8.20
- Analyst Decision
- ADAP Strong Buy
- PROF Strong Buy
- Analyst Count
- ADAP 3
- PROF 2
- Target Price
- ADAP $3.38
- PROF $11.40
- AVG Volume (30 Days)
- ADAP 1.5M
- PROF 38.0K
- Earning Date
- ADAP 08-12-2024
- PROF 10-31-2024
- Dividend Yield
- ADAP N/A
- PROF N/A
- EPS Growth
- ADAP N/A
- PROF N/A
- EPS
- ADAP N/A
- PROF N/A
- Revenue
- ADAP $141,459,000.00
- PROF $7,880,000.00
- Revenue This Year
- ADAP $172.21
- PROF $56.87
- Revenue Next Year
- ADAP N/A
- PROF $161.94
- P/E Ratio
- ADAP N/A
- PROF N/A
- Revenue Growth
- ADAP 99.90
- PROF 16.67
- 52 Week Low
- ADAP $0.42
- PROF $7.11
- 52 Week High
- ADAP $2.05
- PROF $11.69
- Technical
- Relative Strength Index (RSI)
- ADAP 44.14
- PROF 34.57
- Support Level
- ADAP $1.17
- PROF $8.16
- Resistance Level
- ADAP $1.32
- PROF $9.35
- Average True Range (ATR)
- ADAP 0.09
- PROF 0.41
- MACD
- ADAP -0.01
- PROF -0.11
- Stochastic Oscillator
- ADAP 22.58
- PROF 2.34
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.